2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2431

Acquisition of Protective Alleles in Women with Rheumatoid Arthritis through Microchimerism
Abstract Number: 2774

Activation of a Cytosolic DNA Sensor Pathway in the Etiopathogenesis of Sjögren’s Syndrome
Abstract Number: 1063

Activation of Toll-like Receptor 2 in Human Synovium Explants Increase Tissue Turnover and Secretion of Interleukin-6
Abstract Number: 1240

Active Disease Is Associated with Dependency in Inflammatory Arthritis
Abstract Number: 2767

Active Yet Sedentary: The Association of Moderate to Vigorous Physical Activity and Sedentary Behavior with Incident Functional Limitation in Knee OA
Abstract Number: 1185

Acupotomy Therapy for Joint Pain Relief of Knee Osteoarthritis-Systematic Review and Meta-Analysis
Abstract Number: 961

Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Abstract Number: 2283

Adalimumab Therapy in Juvenile Idiopathic Arthritis: Addition of Lidocaine for Prevention of Injection Site Pain or Not? That Is the Question. a Comparison Study
Abstract Number: 2723

Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Abstract Number: 2135

ADAM-17 Is Expressed in the Inflammatory Myopathy, and Is Involved with Interstitial Lung Disease
Abstract Number: 960

ADAM-17 Is Expressed on Rheumatoid Arthritis Synovial Fibroblasts and Mediates Monocyte Migration and Adhesion
Abstract Number: 578

Added Value of Biomarkers Compared to Routine Clinical Parameters for the Prediction of Radiographic Spinal Progression in Axial Spondyloarthritis
Abstract Number: 2967

Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort
Abstract Number: 461

Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?
Abstract Number: 2761

Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].